Strengthening Pharmaceutical Production Capacity through Construction of a New Takaoka Plant
First written in FY2024. 1 of 4 entries say "Achieved", first in FY2025-H1. Latest entry: 2026-04-24.
No other company in this theme has enough history to compare yet.
- 2026-04-24ReframedM&A and Subsidiary Changes
「The Takaoka and Inami plants owned by Kyorin Pharmaceutical Group Factory Co., Ltd., a consolidated subsidiary of ours responsible for the production functions of our Group.」
The Takaoka and Inami plants were shown to be included in the transfer of the generic drug business, changing their previous positioning as part of the Group’s internal production capacity. - FY2025AdvancedAnnual report
「At the Takaoka Plant, which began operations in April 2024, the Company manufactures generic drugs and Mucodyne Tablets, for which the authorities requested increased production, and made its first shipment in July.」
After beginning operations in April 2024, the new Takaoka Plant progressed to manufacturing generic drugs and Mucodyne Tablets and making its first shipment in July of the same year. - FY2025-H1AchievedAnnual report
「The Company is also working to strengthen its stable supply system, including manufacturing generic drugs and Mucodyne, for which the authorities requested increased production, at the Takaoka Plant, which began operations in April 2024.」
The construction of the new Takaoka Plant and expansion of production capacity progressed to the plant's start of operations and the commencement of manufacturing in April 2024. - FY2024First statedAnnual report
「We will also construct a new plant in Takaoka to strengthen pharmaceutical production capacity.」
Construction of a new plant in Takaoka and stronger pharmaceutical production capacity were newly identified as measures to ensure stable supply.